POLQ and neoplasm: While treatment with EGFR tyrosine kinase inhibitors (TKIs) has been reported as effective strategy in patients with EGFR-mutant non-small cell lung carcinoma, including LAC [47], it would seem that LAC patients with tumor POLQ overexpression, which was found to be associated with EGFR-WT status, are not likely to benefit from EGFR-TKI treatment, as compared to LAC patients without POLQ overexpression in the tumor.